- Home
- PTON vs NAMS Comparison
PTON vs NAMS Comparison
Compare PTON & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTON | NAMS |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.1B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PTON | NAMS |
|---|---|---|
| Price | $6.76 | $34.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $9.68 | ★ $45.80 |
| AVG Volume (30 Days) | ★ 8.5M | 1.1M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,455,600,000.00 | $35,243,000.00 |
| Revenue This Year | $1.53 | N/A |
| Revenue Next Year | $1.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 4.91 |
| 52 Week Low | $4.63 | $14.06 |
| 52 Week High | $10.90 | $42.00 |
Technical Indicators
Market Signals| Indicator | PTON | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 41.35 |
| Support Level | $6.31 | $34.70 |
| Resistance Level | $6.80 | $36.60 |
| Average True Range (ATR) | 0.32 | 1.90 |
| MACD | 0.01 | -0.70 |
| Stochastic Oscillator | 52.49 | 5.08 |
Price Performance
Historical ComparisonAbout PTON Peloton Interactive Inc.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product derives revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.